HomeFUNDING

FUNDING

CytoSorbents Awarded $2,897,172 Phase III STTR Contract

This follows the successful completion of Phase I and II STTR contracts of approximately $1.15 million with researchers at Penn State University, previously funded by the U.S. Army Medical Research Acquisition Activity (USAMRAA) and the U.S. Army Medical Research and Material Command (USAMRMC).

HistoSonics Announces $40 Million Financing

HistoSonics notes the breakthrough medical platform offers vision of non-invasive procedures to eliminate diseased tissues and tumors

Alpha Tau Medical Announces Successful Completion of New $26 Million Funding Round

During the last year, Alpha Tau Medical successfully completed its first-in-human clinical trial of Alpha DaRT with squamous cell carcinoma patients from Italy and Israel.

Base Genomics Announces Company Launch and Raises $11 Million USD

Base Genomics is led by a highly experienced team of scientists and clinicians, including Dr Vincent Smith, a world-leader in genomic product development and other prominent leaders.

LaunchPad Medical Wins a Coveted $1.8 Million Michigan-Pittsburgh-Wyss Regenerative Medicine Center Grant

This grant, the largest it has received from the Resource Center, will allow the company to conduct a pivotal animal study and generate all the other required data to file an Investigational Device Exemption (IDE) application with the FDA to start a clinical trial.

LabMinds Secures Financing to Boost Commercial Growth of The REVO® Robotic System

This funding will help drive the commercialization of its automation system as well as facilitate the expansion of LabMinds’ product portfolio.

Ezra Raises $18M Series A

The AI cancer screening startup will use the funding to expand its suite of medical imaging AIs, and launch the Ezra COVID 360 offering.

Sinovac Secures $15 Million in Funding to Accelerate COVID-19 Vaccine Development

The funds to be used to further the development of an inactivated vaccine against COVID-19 named CoronaVac. The two investors each loaned USD $7.5 million in the form of a convertible loan that bears interest, or, at the investor’s election, converts into 7.5% of the total equity interest of Sinovac R&D.

SOLIUS Announces Investment from Human Longevity Inc. to Support Mission of Improving Health, Performance, and Longevity

SOLIUS technology stimulates the production of vitamin D in the skin using a narrow spectrum of ultraviolet B (UVB) light.